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ABSTRACT
CONTEXT AND OBJECTIVE: Despite the high prevalence of vitamin D supplementation, its use remains 
controversial. The objective of this review was to identify and summarize the evidence from Cochrane 
systematic reviews regarding vitamin D supplementation for preventing or treating any clinical condition.
DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based 
Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo. 
METHODS: A search was conducted to identify all Cochrane systematic reviews that fulfilled the inclusion 
criteria. Titles and abstracts were screened by two authors.
RESULTS: We included 27 Cochrane systematic reviews: 10 assessing use of vitamin D for prevention and 
17 for treatment. The reviews found moderate to high quality of evidence regarding the benefit of vi-
tamin D for pregnant women (prevention of adverse events: preterm birth risk [rate ratio, RR 0.36; 95% 
confidence interval, CI 0.14 to 0.93] and low birthweight risk [RR 0.40; 95% CI 0.24 to 0.67]) and for asthma 
patients (reduction of severe exacerbations [RR 0.63; 95% CI 0.45 to 0.88]). No benefit was found regarding 
vitamin D supplementation alone (without calcium) for preventing hip or any new fracture. For all other 
outcomes assessed under various conditions, the current quality of evidence is low or unknown, and 
therefore insufficient for any recommendation. 
CONCLUSION: Based on moderate to high quality of evidence, the Cochrane systematic reviews included 
here showed that there were some benefits from vitamin D supplementation for pregnant women and 
asthma patients and no benefits for preventing fractures.
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A series of national surveys in the United States1 have shown that vitamin supplementation is 
done most commonly in relation to vitamin D. These analyses, relating to 2011-2012, showed 
that the prevalence of vitamin D supplementation was around 40%. After excluding supplemen-
tation using multivitamin or multimineral sources, the frequency of vitamin D supplementation 
was still high (approximately 19%).2 In addition, use of vitamin D supplementation has been 
increasing over the years. Supplementation with this micronutrient (excluding multivitamin/
multimineral sources) was around 5.1% in 1999-2000 (with a difference of 14 percentage points 
from the 2011-2012 prevalence).2,3 The intake of high-dose vitamin D supplements (more than 
1000 IU/day) has also increased. In 1999-2000, a prevalence of 0.3% was reported, versus 15.8% 
in 2011-2012.4 
The number of published papers relating to vitamin D has also increased over time. A quick 
search in MEDLINE (via PubMed), using the strategy (“Vitamin D”[Mesh]) and a broad filter 
of clinical trials, retrieved 192 references in 2016, versus 75 in 1996 (a mean of 150 references 
per year was found over the period considered). Despite the popularity of vitamin D use and the 
high number of studies on this topic, the efficacy and safety of its supplementation are still a mat-
ter for debate in the literature.5 Because of the variety of dosages and formulations for vitamin D 
supplements and significant clinical heterogeneity between the conditions under which vitamin 
D is hypothesized to have benefits, the conclusions are still confusing.
Therefore, considering (a) the vast use of vitamin D supplementation, (b) the high number 
of primary studies published and (c) the controversy that continues in the literature, a systematic 
synthesis of the available evidence, such as the present review, is essential.
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OBJECTIVE
To identify and summarize the evidence from Cochrane system-
atic reviews regarding vitamin D supplementation for preventing 
or treating any clinical condition.
METHODS
Design and setting
A review of Cochrane systematic reviews was conducted 
within the Discipline of Evidence-based Medicine of Escola 
Paulista de Medicina, Universidade Federal de São Paulo 
(EPM-Unifesp). This article was specifically developed for the 
section Cochrane Highlights, which is an initiative for dis-
seminating Cochrane reviews. This initiative results from a 
formal partnership between the São Paulo Medical Journal 
and Cochrane, and it is supported by Cochrane Brazil.
Inclusion criteria
Types of study
We included any completed Cochrane systematic reviews pub-
lished in the Cochrane Database of Systematic Reviews (CDSR). 
Protocols of systematic reviews and withdrawn or outdated ver-
sions of systematic reviews were not included. There was no limi-
tation regarding date of publication.
Types of participants
Healthy individuals or those diagnosed with any clinical condi-
tion were included, regardless of age, ethnicity or sex.
Types of intervention
We considered systematic reviews on vitamin D supplemen-
tation, in any form (active or non-active), presentation (cap-
sules or oral solution), dose (high, conventional or under-
doses), regimen or duration of use, as a single or combined 
intervention. We did not consider reviews in which the clini-
cal question involved vitamin D in combination with other 
interventions and in which it was not possible to assess the 
effect of vitamin D in isolation. 
Types of outcomes
We considered any clinical or laboratory outcomes evaluated by 
the authors of the systematic reviews.
Search for reviews
We conducted a systematic search in the Cochrane Database of 
Systematic Reviews (CDSR) (via Wiley) on April 4, 2017, sen-
sitively using the MeSH term “Vitamin D” in titles, abstracts 
and keywords. 
Selection of reviews
The titles and abstracts were read by two out of three authors 
(MVM, RLP or DVP) independently. The systematic reviews that 
met the inclusion criteria was selected. Any disagreement was 
solved by consulting a further author (RR or COCL). 
Presentation of results
The results from the search and the systematic reviews included were 
presented through a descriptive structure (qualitative synthesis).
RESULTS
Search results
Our search strategy retrieved 53 references and, after screening 
the titles and abstracts, 28 systematic reviews were preselected. 
After assessing full texts, 27 reviews6-32 were found to fulfill our 
inclusion criteria and were included for qualitative analysis. 
One systematic review that assessed vitamin D plus calcium sup-
plementation for treating corticosteroid-induced osteoporosis 
was excluded because it was not possible to evaluated the effect 
of vitamin D in isolation.33
Reviews included
A summary of the issues, objectives, main findings and quality of 
evidence among the 27 systematic reviews included is presented 
below. We also present a brief individual summary of each review 
included, according to the clinical situation. For detailed expla-
nations, the full versions can be viewed in the box in Table 1.6-32,34 
1. Asthma
The review6 evaluated the effect of vitamin D for prevent-
ing asthma attacks or improving disease control, in compari-
son with placebo or no intervention. Nine randomized clini-
cal trials (RCTs) involving 1,093 participants were included. 
The majority of the participants were considered to have mild 
to moderate asthma. The results showed that vitamin D pres-
ents benefits relating to:
• Risk of exacerbations requiring systemic corticosteroids 
(number of events per participant per year, during a follow-
up of six to 12 months (rate ratio, RR 0.63; 95% confidence 
interval, CI 0.45 to 0.88; three RCTs; 680 participants; high-
quality evidence); 
• Risk of experiencing at least one exacerbation requiring an 
emergency department visit or hospitalization or both (odds 
ratio, OR 0.39; 95% CI 0.19 to 0.78; seven RCTs; 963 partici-
pants; high-quality evidence).
There was no difference between the intervention groups for 
the following outcomes: predicted percentage of forced expiratory 
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Asthma6 500 IU/day to 4000 IU/day
Reduction of risk of exacerbations requiring systemic 
corticosteroids and risk of having at least one 
exacerbation requiring an emergency department visit or 
hospitalization or both.
No difference in predicted percentage of forced 
expiratory volume in one second, asthma control test 
scores or risk of serious adverse events.
Moderate to high
Atopic eczema7 1000 IU/day to 1600 IU/day No reliable evidence for benefits or harm. -
Sickle cell disease8 240,000 to 600,000 IU in six weeks Higher serum vitamin D levels at eight, 16 and 24 weeks. -
Multiple sclerosis9 4,000 IU/day to 40,000 IU/day No reliable evidence for benefits or harm. -
Epilepsy10 2,000 IU/day No reliable evidence for benefits or harm. -
Prevention of fractures in 
postmenopausal women  
and older men11
Many schemes and formulations 
of vitamin D. For detailed 
explanations, see full version.
No statistical difference in prevention of hip fracture or 
any new fracture (vitamin D alone, without calcium).
High
Prevention of adverse 
outcomes in pregnancy12
200 IU/day to 2000 IU/day
35,000 IU/week
200,000 IU to 600,000 IU in single dose
Reductions in preterm birth and in low birthweight.
No difference in preeclampsia,  
gestational diabetes or adverse events.
Moderate
Chronic painful  
conditions in adults13
1,200 IU/day to 100,000 IU/day
50,000 IU/week
150,000 IU in single dose
No difference in pain relief or pain-related outcomes. -
Prevention of cancer in adults14 300 IU/day to 3333 IU/day
No reduction in cancer occurrence rate.
Slightly reduction in all-cause mortality.
Slight reduction in cancer mortality favoring  
vitamin D (only for cholecalciferol form).
Low to moderate
Cystic fibrosis15
800 IU/day to 1600 IU/day
250,000 IU in single dose
No difference in overall and respiratory outcomes or in 
vitamin D deficiency disorders.
-
Prevention of mortality  
among adults16
400 IU/day to 100,000 IU/day
18,000 IU/day to 100,000 IU/day
300,000 IU in single dose
Small reductions in all-cause mortality  
and in cancer-related mortality.
Higher risk of nephrolithiasis in  
treated group (cholecalciferol).
-
Recovery from hip fracture 
among elderly people17
800 IU/day to 2,000 IU/day
50,000 IU in single dose to 100,000 
IU in single dose
No difference in mortality or risk of fall-related injury. -
Latent autoimmune diabetes 
(LADA) in adults18
Alfacalcidol 0.25 ug/day No reliable evidence for benefits or harm. -
Sexual dysfunction among 
patients with chronic  
kidney disease19
Calcitriol 0.25-1.5 µg/d No reliable evidence for benefits or harm. -
Cases of chronic kidney  




No difference in mortality or risk of dialysis. -
Cases of chronic kidney  
disease requiring dialysis21
Many schemes and formulations 
for vitamin D. For detailed 
explanations, see full version.
No reliable evidence for benefits or harm. -
Metabolic bone disease  
in children with chronic  
kidney disease22
Many schemes and formulations 
for vitamin D. For detailed 
explanations, see full version.
No reliable evidence for benefits or harm. -
Kidney transplant recipients23
Many schemes and formulations 
of vitamin D. For detailed 
explanations, see full version.
No reliable evidence for benefits or harm. -
Autosomal dominant  
polycystic kidney disease24
Calcitriol 0.25 to 1 µg/day No reliable evidence for benefits or harm. -
Prevention of bone outcomes 
in healthy children25
133 IU/day to 2000 IU/day
No differences in total body bone mineral content, hip 
bone mineral density, lumbar spine bone mineral density 
or forearm bone mineral density.
-
Table 1. Main characteristics relating to clinical situation, intervention, findings and quality of evidence among the systematic reviews included
Continue...
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volume in one second (mean difference, MD 0.48; 95% CI -0.93 to 
1.89; four RCTs; 387 participants; high-quality evidence); asthma 
control test scores (MD -0.08; 95% CI -0.70 to 0.54;  three RCTs; 
713 participants; high-quality evidence); and risk of serious adverse 
events (OR 1.01; 95% CI 0.54 to 1.89; five RCTs, 879 participants; 
moderate-quality evidence). These results should be taken carefully 
and their clinical relevance needs to be assessed by an asthma spe-
cialist, preferably supported by cost-effectiveness analysis, before 
any recommendation for practice is made. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD011511.pub2/full.
2. Atopic eczema
The review7 evaluated dietary supplementation, including vita-
min D, for treatment of atopic dermatitis. Among the 11 RCTs 
included in the full review, two studies (n = 63) evaluated the 
effects of vitamin D supplementation, and showed that there was 
no benefit from vitamin D use for primary efficacy outcomes 
(participant/parent-rated symptoms of atopic eczema, such as 
pruritus or sleep loss, or reduction in the number of flares or 
need for other treatments) or secondary efficacy outcomes (over-
all severity assessed by participants or physicians, quality of life 
or adverse events). Both studies had limited numbers of partic-
ipants, overall low methodological quality and short follow-up 
periods, which precluded any definitive conclusion regarding the 
effect of vitamin D on atopic dermatitis. Therefore, the authors 
concluded that the current evidence was insufficient for routinely 
recommending vitamin D for such clinical situations in practice. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD005205.pub3/full. 
3. Sickle cell disease
Sickle cell disease is associated with multiple micronutrient defi-
ciencies. The review8 aimed to investigate the effects of vitamin D 
supplementation on sickle cell disease and only one RCT (39 par-
ticipants) was found.
Compared with placebo, the vitamin D group had significantly 
higher serum vitamin D levels after: 
• Eight weeks (MD 29.79; 95% CI 26.63 to 32.95; 37 participants; 
moderate-quality evidence);
• 16 weeks (MD 12.67; 95% CI 10.43 to 14.90);
• 24 weeks (MD 15.52; 95% CI 13.50 to 17.54). 
No statistical significance was found in relation to any other 
outcome evaluated through this RCT. This study was classified 
as containing a high risk of attrition bias, because only 25 of the 
37 randomized participants (67%) completed the six-month fol-
low-up. The authors concluded that no practical recommendation 
could be made regarding supplementation of vitamin D among 
patients with sickle cell disease. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD010858.pub2/full.
4. Multiple sclerosis 
The review9 evaluated the effects of vitamin D for multiple sclerosis 
and included only one small RCT (n = 49; 52-week follow-up), which 




Prevention of nutritional rickets 
in term-born children26
400 IU/day No reduction in the risk of rickets. -
Prevention of infections in 
children under five years of age27
400 IU/day to 2500 IU/day
No differences in all-cause mortality, cause-specific 
mortality, risk of pneumonia or risk of diarrhea.
Low to moderate
Children and adults  
with HIV infection28
4,000 IU/day to 7,000 IU/day
100,000 IU in single dose
No difference in mortality among HIV patients with  
active tuberculosis or in CD4 cell count.
Very low to 
moderate
Active tuberculosis29 200/day to 600 IU/day
No differences in mortality, tuberculosis cure at 6 months 
or sputum-smear or sputum-culture positivity at 8 weeks.
-
Prevention of falls  
among stroke victims30
Many schemes and formulations 
for vitamin D. For detailed 
explanations, see full version.
No differences in risk of falls or in the number of fallers 
(compared with use of placebo or alendronate).
-
Prevention of falls among 
elderly people in care  
facilities and hospitals31
Many schemes and formulations 
for vitamin D. For detailed 
explanations, see full version.
Reduction in rate of falls.
No reduction in the risk of falling.
-
Prevention of falls among 
elderly people living  
in the community32
800 IU/day to 2000 IU/day No difference in the risk of falling. -
*GRADE34 (Grading of Recommendations Assessment, Development and Evaluation) is used for assessment of the quality of the body of evidence.
Table 1. Continuation.
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compared serial doses of vitamin D versus placebo. The  authors 
reported that there was a reduction in the relapse rate, a higher pro-
portion of relapse-free patients and a reduction in the EDSS score 
(i.e. the disability score) in the intervention group. However, no 
numerical data were provided. In additional, the RCT included had 
a small sample size and significant methodological limitation, and 
so presented substantial risk of bias. Therefore, the current evidence 
did not provide any solid conclusion regarding the effects of vitamin 
D on multiple sclerosis.
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD008422.pub2/full.
5. Epilepsy
The review10 assessed the effects of different interventions on 
epilepsy and included 15 RCTs, but only two of them (n = 274) 
evaluated the use of vitamin D. However, no data were available 
regarding freedom from seizures, seizure frequency, quality of 
life, cognitive function, reduced side effects from antiepileptic 
drugs or any other outcome considered by the review. The stud-
ies had significant methodological limitation and therefore high 
risk of bias. The authors’ conclusion was that no reliable evidence 
was found to support use of vitamin D among epileptic patients. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD004304.pub2/full.
6. Postmenopausal women and older men
The purpose of the review11 was to determine the effects of vita-
min D or related compounds for preventing fractures among 
postmenopausal women and older men. This review included 53 
RCTs (n = 91,791) and the results showed that vitamin D alone 
was not effective for preventing:
• Hip fracture (RR 1.12; 95% CI 0.98 to 1.29; 11 RCTs; n = 27,693);
• Any new fracture (RR 1.03; 95% CI 0.96 to 1.11; 15 RCTs; n = 28,271).
The authors concluded that with the current evidence, vitamin 
D alone was unlikely to prevent fractures. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD000227.pub4/full.
7. Prevention of adverse outcomes in pregnancy
The aim of the systematic review12 was to assess the effects of oral 
supplementation with vitamin D during pregnancy for improving 
maternal and neonatal outcomes. The review included 15 RCTs 
(n = 2,833) and it showed that vitamin D supplementation during 
pregnancy provided benefits regarding the following outcomes:
• Risk of preterm birth (RR 0.36; 95% CI 0.14 to 0.93; three 
RCTs; n = 477; moderate-quality evidence);
• Risk of low birthweight (RR 0.40; 95% CI 0.24 to 0.67; three 
RCTs; n = 493; moderate-quality evidence).
There was no statistical difference between the groups regarding 
the risk of preeclampsia (RR 0.52; 95% CI 0.25 to 1.05; two RCTs; 
n = 219; low-quality evidence), gestational diabetes (RR 0.43; 95% 
CI 0.05 to 3.45; two RCTS; n = 219; very low-quality evidence) or 
adverse effects (RR 0.17; 95% CI 0.01 to 4.06; one RCT; n = 135; 
low-quality evidence). In the light of these results, the authors con-
cluded that the benefits of vitamin D supplementation as part as 
routine antenatal care were still unclear and that further studies 
were needed in order to confirm whether there was any benefit in 
relation to maternal and neonatal outcomes. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD008873.pub3/full.
8. Chronic painful conditions in adults
The review13 assessed the efficacy and safety of vitamin D supple-
mentation versus placebo or versus active comparators, for adults 
with chronic painful conditions. Ten RCTs (n = 811), including 
people with rheumatoid arthritis (four RCTs), knee osteoarthri-
tis (two RCTs), polymyalgia rheumatic (one RCT), “non-spe-
cific” musculoskeletal pain (one RCT), “diffuse” musculoskele-
tal pain (one RCT) and fibromyalgia (one RCT), were included. 
These  studies were very heterogeneous regarding clinical and 
methodological characteristics, and therefore no quantitative 
analysis was possible. No statistical difference was demonstrated 
for any primary outcome (number of participants with 50% pain 
relief, improvement in overall impression of pain change or any 
other pain-related outcome). Based on these results, no recom-
mendation for any vitamin D supplementation for chronic pain-
ful conditions could be made. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD007771.pub3/full.
9. Prevention of cancer in adults
The aim of the review14 was to assess the effectiveness and safety 
of vitamin D (cholecalciferol, ergocalciferol, alfacalcidol and cal-
citriol) for preventing cancer, and included 18 RCTs (n = 50,623). 
The following results were found:
• Risk of cancer: no significant reduction through vitamin D sup-
plementation over a follow-up of 0.5 to seven years (RR 1.00; 95% 
CI 0.94 to 1.06; 18 RCTs; n = 50,623; moderate-quality evidence);
• All-cause mortality: through vitamin D supplementation over 
a follow-up of 0.5 to 7 years (RR 0.93; 95% CI 0.88 to 0.98; 
15 RCTs; n = 49,866; low-quality evidence);
• Cancer-related mortality: no significant reduction through cho-
lecalciferol (RR 0.88; 95% CI 0.78 to 0.98; four RCTs; n = 44,492; 
low-quality evidence). 
This review did not show any evidence of effects from any pre-
sentation of vitamin D in relation to reducing the risk of cancer. 
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It was found that there was a general need for more studies in 
order to make any recommendations regarding clinical practice. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD007469.pub2/full.
10. Cystic fibrosis
The review15 examined the effects of vitamin D supplementa-
tion for cystic fibrosis patients, and  included six randomized 
and quasi-randomized controlled studies (n = 239). No improve-
ments in general or respiratory outcomes or in vitamin D defi-
ciency disorders (osteopenia or osteoporosis) were found. 
The  high clinical and methodological heterogeneity between 
studies precluded meta-analysis. The number of published stud-
ies was small and there was currently no evidence of clinical ben-
efit from vitamin D supplementation. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD007298.pub4/full.
11. Prevention of mortality among adults
The objective of the review16 was to assess the benefits and harm 
from vitamin D supplementation in relation to preventing mortal-
ity. It included 159 RCTs, but only 56 (n = 95,286) reported usable 
data regarding mortality. The following results were found for the 
comparisons of cholecalciferol versus placebo or no intervention:
•  All-cause mortality: reduction of 6% over a seven-year follow-up 
[(RR 0.94; 95% CI 0.91 to 0.98; number needed to treat (NNT) = 
150; 38 RCTs; n = 75,927; moderate-quality evidence)];
• Cancer-related mortality; reduction of 12% (RR 0.88; 95% CI 
0.79 to 0.98; four RCTs; n = 44,492; moderate-quality evidence). 
For the comparisons of cholecalciferol plus calcium versus 
placebo or no treatment, the risk of nephrolithiasis was higher 
in the treated group (RR 1.07; 95% CI 1.02 to 1.34; four RCTs; 
n = 42,876). The risk of attrition bias due to the substantial drop-
out of participants and the risk of outcome reporting bias regard-
ing mortality weakened the current evidence. Further RCTs with 
strong methodological and reporting quality would be needed in 
order to draw any practical conclusion. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD007470.pub3/full.
12. Recovery from hip fracture among elderly people
The aim of the review17 was to evaluate the effects of nutritional 
interventions among elderly people who were recovering from 
hip fractures. It included 24 RCTs, but only four RCTs evalu-
ated vitamin D supplementation. There was no evidence of any 
effects from vitamin D supplementation regarding any primary 
or clinical outcomes such as mortality or the risk of fall-related 
injury. Currently, there was no evidence that vitamin D had any 
beneficial effect among older patients who were recovering from 
hip fractures.
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD001880.pub6/full.
13. Latent autoimmune diabetes (LADA) in adults
The review18 aimed to assess the effects of different interven-
tions relating to latent autoimmune diabetes (LADA), which is 
a kind of type 1 diabetes with slow progression to insulin depen-
dency. Ten RCTs (n = 1,109) were included, but only one related 
to vitamin D. This study compared vitamin D plus insulin versus 
insulin alone and showed that the peptide C levels in the com-
bined group remained steady, but that these levels decreased 
in the insulin-alone group (368 to 179 pmol/L; P = 0.006) over 
12 months of follow-up. The lack of methodologically high-qual-
ity studies prevented any practical recommendation regarding 
the use of vitamin D for treatment of LADA. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD006165.pub3/full.
14. Sexual dysfunction among patients with chronic kidney 
disease (CKD)  
The purpose of the review19 was to evaluate the benefits and harm 
of interventions for treating sexual dysfunction among CKD 
patients. It included 15 RCTs (n = 352 patients), but only one 
RCT (n = 15) aimed to assess the efficacy of vitamin D. No sound 
benefits were found among the outcomes reported (endocrine 
parameter levels) in this study. The small sample size and the 
high risk of bias attributed to this study prevented any conclu-
sion regarding the use of vitamin D for treating sexual dysfunc-
tion among CKD patients. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD007747.pub2/full.
15. Cases of chronic kidney disease (CKD) not requiring dialysis 
The objective of the review20 was to evaluate the efficacy of vita-
min D for patients with CKD who were not requiring dialysis. 
Sixteen RCTs (n = 894) were included. Some analyses showed 
lower serum parathyroid hormone (PTH) concentration and 
higher calcium and phosphorus concentration, but no benefits 
in relation to primary clinical outcomes, such as mortality or risk 
of dialysis, were found. The authors concluded that there were 
insufficient data to determine the effect of vitamin D on mor-
tality and relevant clinical outcomes among chronic non-dialytic 
renal patients. 
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For further details, refer to the original abstract, available at: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008175/full.
16. Cases of chronic kidney disease (CKD) requiring dialysis
The review21 aimed to evaluate the efficacy and safety of vitamin 
D compounds in CKD patients requiring dialysis. It included 
60 RCTs (n = 2,773) that evaluated multiple formulations, routes 
and schedules for administration of vitamin D compounds. 
No clinically relevant outcomes favored the intervention group in 
any comparisons. Some analyses showed decreased serum PTH 
levels and a tendency towards higher calcium and phosphate 
concentrations. In the light of the low quality and poor reporting, 
and considering the marked clinical and methodological hetero-
geneity of the studies available, no strong practical recommenda-
tions could be made. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005633.pub2/full.
17. Metabolic bone disease in children with chronic kidney 
disease (CKD)
The purpose of the review22 was to examine the benefits and harm 
of interventions for prevention and treatment of metabolic bone 
disease in children with CKD. This review included 18 RCTs 
(n = 576) and evaluated eight different interventions, most of them 
including at least one vitamin D preparation. Other than differ-
ences in PTH levels between groups in some of these comparisons, 
no other clinical or primary outcome was improved through vita-
min D supplementation. Therefore, no solid recommendation in 
favor of vitamin D supplementation could be made.
For further details and more information about the comparisons 
included, refer to the original abstract, available at: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD008327.pub2/full.
18. Kidney transplant recipients 
The aim of the review23 was to evaluate the use of interven-
tions for preventing bone disease following kidney transplanta-
tion. Twenty-four RCTs (n = 1,299) were included. Studies that 
assessed use of vitamin D sterols and other interventions such 
as use of bisphosphonates, calcitonin and other substances were 
considered. The analysis on vitamin D sterol alone versus pla-
cebo or no treatment did not show any reduction in the risk of 
fractures or other clinical outcomes such as all-cause mortality. 
Some improvement in bone mineral density (lumbar spine and 
femoral neck) was reported in one RCT. Because of the lack of 
studies of high methodological quality assessing the use of vita-
min D alone for preventing bone disease, it was difficult to come 
to any practical conclusion before further studies investigating 
this question are developed. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005015.pub3/full.
19. Autosomal dominant polycystic kidney disease (ADPKD)
The review24 evaluated the effects of interventions for preventing 
progression of ADPKD, in relation to kidney function, kidney 
endpoints, kidney structure, patient-centered endpoints and the 
adverse effects of these treatments. This review included 30 stud-
ies, but only one RCT (n = 34) evaluated vitamin D supplemen-
tation, which was done in comparison with Chinese medicine 
(herbs). The data were sparse and inconclusive, and the authors 
were unable to make any solid recommendations. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD010294.pub2/full.
20. Prevention of bone outcomes in healthy children 
The aim of the review25 was to determine the effectiveness of vita-
min D supplementation for increasing bone mineral density in 
children. Six RCTs were included (n = 884). No statistically sig-
nificant differences between the vitamin D and control groups 
were found in relation to: 
• Total body bone mineral content (standard mean difference, SMD 
0.1; 95% CI -0.06 to 0.26; 5 RCTs; n = 672; high-quality evidence);
• Hip bone mineral density (SMD 0.06; 95% CI -0.18 to 0.29; 
4 RCTs; n = 639; moderate-quality evidence);
• Lumbar spine bone mineral density (SMD 0.15; 95% CI -0.01 
to 0.31; 5 RCTs; n = 660);
• Forearm bone mineral density (SMD 0.04; 95% CI -0.36 to 
0.45; 3 RCTs; n = 427). 
The authors concluded that the results did not support supple-
mentation to improve bone mineral in children. 
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD006944.pub2/full.
21. Prevention of nutritional rickets in term-born children
The review26 aimed to evaluate the effects of any intervention 
for prevention of rickets in term-born children. It included 
three RCTs and one non-randomized clinical trials (n = 1,700). 
Only three studies evaluated use of vitamin D alone, but in two of 
these studies there were no occurrences of rickets in either group. 
One study comparing vitamin D (400 IU per day for 12 months) 
versus no intervention showed that there was a statistical reduc-
tion in the risk of occurrence of rickets (RR 0.04; 95% CI 0 to 
0.71; one RCT; n = 676). Even in the light of this result, the 
authors considered it reasonable to offer vitamin D or calcium 
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for prevention of rickets to all children up to two years of age. 
However, they pointed out that further studies would be needed 
to investigate the effects in higher-risk subgroups and to investi-
gate possible adverse effects. 
This recommendation needs to be better evaluated, consid-
ering that 
1. Only one study contributed towards this conclusion; 
2. The evaluation on the risk of bias for this systematic review, 
published in 2007, did not follow the current standard (i.e. the 
risk-of-bias table from the Cochrane Collaboration); and 
3. No assessment of the quality of the body of the evidence was 
required by the Cochrane Collaboration at the time when this 
systematic review was published.  
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD006164.pub2/full.
22. Prevention of infections in children under five years of age
The purpose of the review27 was to evaluate the role of vitamin D 
supplementation in preventing infections in children under five 
years of age. Four RCTs (n = 3,198) were included. No difference 
between the vitamin D and control groups (placebo or no sup-
plementation) was found in relation to the following outcomes:
• All-cause mortality (mortality due to any cause of death) (RR 1.43; 
95% CI 0.54 to 3.74; one RCT; n = 3,046; low-quality evidence);
• Cause-specific mortality (mortality due to pneumonia, tuber-
culosis, diarrhea or malaria) (RR 1.50; 95% CI 0.42 to 5.30; 
one RCT; n = 3,046; low-quality evidence);
• Risk of a radiologically confirmed first or only episode of pneu-
monia (RR 1.06; 95% CI 0.89 to 1.26; two RCTs; n = 3,134; 
moderate-quality evidence);  
• Risk of diarrhea (two RCTs; no numerical data provided).
No study investigating other infectious diseases such as tuber-
culosis or malaria was found. The authors concluded that the impli-
cations of this systematic review were limited because of the low 
availability of primary studies. 
For further details, refer to the original abstract, available from: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD008824.pub2/full.
23. Children and adults with HIV infection 
The review28 aimed to evaluate the efficacy and safety of micronu-
trient supplementation for reduction of morbidity and mortality 
among adults and children with HIV infection. Thirty-three RCTs 
were included, but only five (n = 447) were on vitamin D (alone or 
in combination with calcium). The results showed that vitamin D 
did not provide any benefit in relation to the following outcomes:
• Mortality among HIV patients with active tuberculosis (RR 1.15; 
95% CI 0.65 to 2.02; one RCT; n = 131; very low-quality evidence);
• CD4 cell count (data from four RCTs, not pooled; n = 288).
The authors concluded that further larger RCTs, with strong 
methodological quality, using individual supplementation of vita-
min D would be needed in order to build a baseline of evidence.
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD003650.pub4/full.
24. Active tuberculosis
The objective of the review29 was to assess the effects of oral nutri-
tional supplements among individuals receiving anti-tuberculo-
sis drug therapy to treat active tuberculosis. Eleven RCTs eval-
uated the effects of vitamin D supplementation. The results 
showed that vitamin D did not provide any benefit in relation to 
the following:
• Mortality (RR 0.96; 95% CI 0.81 to 1.12; seven RCTs; n = 2,649);
• Tuberculosis cure at six months (RR 0.99; 95% CI 0.75 to 1.31; 
one RCT; n = 151);
• Sputum-smear or sputum-culture positivity at eight weeks (RR 
0.81; 95% CI 0.54 to 1.20; six RCTs; n = 856). 
The authors concluded that there was no reliable evidence that 
would support vitamin D supplementation among people who 
were being treated for active tuberculosis. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD006086.pub4/full.
25. Prevention of falls among stroke victims
Falls are a common complication after stroke. Around 7% of 
stroke victims suffer falls in the first week after stroke onset. 
The  objective of the review30 was to evaluate the effectiveness 
of interventions for preventing falls among these individuals. 
It included ten RCTs, but only two were on vitamin D. One RCT 
(n = 85) compared vitamin D versus placebo among women who 
had been institutionalized after suffering a stroke, and now pre-
sented low serum vitamin D levels. The second RCT compared 
alfacalcidol versus alendronate among individuals who were 
hospitalized after stroke. For both studies, there was no statis-
tical difference between the vitamin D and comparison groups 
regarding the risk of falls and the number of fallers. The authors 
concluded that these data should be considered provisional until 
further studies had been developed. 
For further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD008728.pub2/full.
26. Prevention of falls among elderly people  in care facilities 
and hospitals
The review31 aimed to evaluate the effectiveness of interven-
tions to reduce falls among elderly people. It included 60 RCTs 
(43 conducted in healthcare facilities and 17 in hospitals), total-
ing 60,345 participants. In the healthcare facilities, the vitamin 
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D group had a lower fall rate, defined as the number of falls per 
person-year (RR 0.63; 95% CI 0.46 to 0.86; five RCTs; n = 4,603), 
but did not have a lower risk of falling, defined as the number of 
people falling (i.e. fallers) (RR 0.99; 95% CI 0.9 to 1.08; six RCTs; 
n = 5,186). No measurement of the quality of the body of evi-
dence was reported in this systematic review. The authors con-
cluded that, in care facilities, vitamin D supplementation seemed 
to be effective in reducing the fall rate.
For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005465.pub3/full.
27. Prevention of falls among elderly people living in the community
The review32 aimed to evaluate the effects of interventions to pre-
vent falls among the elderly population. The authors included 
159 RCTs, but only 7 were on vitamin D (n = 9,324). No benefit 
from vitamin D regarding the risk of falls was found (RR 0.96; 
95% CI 0.89 to 1.03; 13 RCTs; n = 26,747). The authors concluded 
that vitamin D supplementation did not seem to reduce the num-
ber of falls. 




This study included 27 Cochrane systematic reviews: 10 related 
to prevention and 17 assessed use of vitamin D as a therapeutic 
option. Among the preventive systematic reviews, five focused 
on healthy individuals for prevention of death,16 cancer,14 and 
other adverse outcomes.12,25,27 Despite the considerable number 
of Cochrane reviews, eight of them did not present any reliable 
evidence regarding benefits or harm from vitamin D, includ-
ing reviews on clinical situations in which use of vitamin D is 
frequently observed in clinical practice, such as in relation to 
multiple sclerosis9 and  atopic eczema.7 Thus, in those reviews, 
the  authors were unable to provide recommendations regard-
ing the benefits and risks of vitamin D. 
Currently, there are major concerns and inconsistencies regard-
ing vitamin D use in clinical practice. Although its use has been 
disseminated by the media, and is widespread among healthcare 
professionals and patients, there are few clinical studies supporting 
this practice. Moreover, the existing studies present poor method-
ological quality, thus leading to uncertain results. 
It is important to highlight that most of the trials providing 
the current evidence were methodologically inappropriate due to 
small sample sizes, insufficient follow-up periods or unclear or 
inadequate methods for randomization and blinding. Furthermore, 
there was huge clinical and methodological heterogeneity among 
clinical trials with the same PICO (P = population, I = intervention, 
C = comparison, O = outcomes), which precluded additional quan-
titative synthesis. All of these features limited the quality of cur-
rent available evidence for relevant outcomes. 
A second point that deserves discussion is that many of the reviews 
included were planned, conducted or published some years ago, and 
therefore were based on early versions of the Cochrane Handbook, 
which were less detailed and complex than the current version (http://
training.cochrane.org/handbook). As an example, the inclusion cri-
teria and methods for assessing the quality of clinical trials were not 
refined as they are now. Moreover, Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) is a new approach 
that was not yet mandatory for Cochrane reviews. Implementation 
of the Cochrane Risk of Bias Table, and mandatory use of GRADE 
and Methodological Expectations of Cochrane Intervention Reviews 
(MECIR) have contributed towards improving the methodological 
rigor of Cochrane reviews over the years. Therefore, it is reasonable to 
assume that older reviews may not present the same quality as recent 
reviews, which could limit the applicability of findings. 
Regarding the implications of these Cochrane reviews for clini-
cal practice,  moderate to high-quality evidence of benefit from 
vitamin D for pregnant women (prevention of maternal and child 
adverse outcomes) and for asthma patients (reduction of severe 
exacerbations) was found. Additionally, no benefit from vitamin 
D supplementation alone (without calcium) for preventing hip 
fracture or any new fracture was found. For all other benefits or 
harm, the current quality of evidence was low or unknown, and 
therefore insufficient for any recommendations.
Regarding the implications of this study for further research, 
it was found that well-designed and well-conducted randomized 
clinical trials are essential for assessing the effectiveness and safety 
of vitamin D for many clinical situations, in which ‘off-label use’ is 
already commonly observed in clinical practice. Moreover, a num-
ber of core questions need to be addressed, including determining 
definitions for the following: the normal serum levels of vitamin 
D; the most appropriate type of vitamin D supplementation; the 
optimal doses for vitamin D supplementation; the most accurate 
method for assessing serum vitamin D levels; and the relationship 
between vitamin D and the risk of diseases. 
CONCLUSION
This study identified 27 Cochrane reviews that provided evidence 
of quality ranging from unknown to high, in relation to vita-
min D supplementation as preventive or therapeutic interven-
tion. Vitamin D was found to present some benefit for pregnant 
women and asthma patients and no benefit when administered 
alone (without calcium) for preventing fractures. For all other 
likely benefit or harm that has been evaluated through Cochrane 
reviews, the current quality of evidence is low or unknown, and 
therefore insufficient for any sound conclusion.
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